Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
The implication of DNA hypermethylation in the pathogenesis of myelodysplastic syndromes (MDS) provides a rationale for using hypomethylating agents such as azacitidine. Growing evidence suggests that azacitidine may reverse epigenetic gene silencing at specific genomic targets. AZA-001 established azacitidine as the first agent to provide a significant overall survival benefit in MDS patients. These data confirmed that azacitidine has a progressively cumulative effect on the MDS clone and support the value of maintenance therapy. Prolonged survival was independent of achieving complete response. Azacitidine in combination with histone deacetylase inhibitors might offer better efficacy by modulating the methylation and acetylation states of silenced genes.
Silverman
Lewis R
LR
Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA. lewis.silverman@mssm.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D001803:Blood Transfusion; D044127:Epigenesis, Genetic; D020868:Gene Silencing; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001374:Azacitidine